Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation: Heart Failure
Search: search_blue_button Advanced Search
Circulation: Heart Failure. 2009;2:361-369
Published online before print May 13, 2009, doi: 10.1161/CIRCHEARTFAILURE.108.827139
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2/4/361    most recent
CIRCHEARTFAILURE.108.827139v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Win, T. S.
Right arrow Articles by Pettigrew, G. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Win, T. S.
Right arrow Articles by Pettigrew, G. J.
Related Collections
Right arrow Animal models of human disease
Right arrow Transplantation
Right arrow CV surgery: transplantation, ventricular assistance, cardiomyopathy
Right arrow Other Vascular biology

Original Articles

Donor CD4 T Cells Contribute to Cardiac Allograft Vasculopathy by Providing Help for Autoantibody Production

Thet Su Win, MB, BChir; Sylvia Rehakova; Margaret C. Negus; Kourosh Saeb-Parsy, PhD, FRCS; Martin Goddard, FRCS, FRCPath; Thomas M. Conlon, PhD; Eleanor M. Bolton, PhD; J. Andrew Bradley, PhD, FRCS and Gavin J. Pettigrew, MD, FRCS

From the Department of Surgery (T.S.W., S.R., M.C.R., K.S.P., T.M.C., E.M.B., J.A.B., G.J.P.), Addenbrooke’s Hospital, Cambridge, United Kingdom; and Department of Pathology (M.G.), Papworth Hospital, Papworth Everard, United Kingdom.

Correspondence to Gavin J. Pettigrew, MD, FRCS, Department of Surgery, Box 202, Addenbrooke’s Hospital, Cambridge CB2 0QQ, United Kingdom. E-mail gjp25{at}cam.ac.uk

Received October 14, 2008; accepted April 20, 2009.

Background— The development of autoantibody after heart transplantation is increasingly associated with poor graft outcome, but what triggers its development and whether it has a direct causative role in graft rejection is not clear. Here, we study the development of antinuclear autoantibody in an established mouse model of heart allograft vasculopathy.

Methods and Results— Humoral vascular changes, including endothelial complement staining, were present in bm12 heart grafts, explanted 50 days after transplantation. Alloantibody was not detectable, but long-lasting autoantibody responses developed in C57BL/6 recipients from the third week after transplantation. No autoantibody was generated if donor CD4 T cells were depleted before heart graft retrieval or in recipients that lacked B-cell major histocompatibility complex class II expression, indicating that humoral autoimmunity is a consequence of donor CD4 T-cell allorecognition of the major histocompatibility complex class II complex on recipient autoreactive B cells. An effector role for autoantibody in graft rejection was confirmed by abrogation of humoral vascular rejection, and attenuation of vasculopathy, in B-cell deficient recipients and by development of vascular obliteration and accelerated rejection in recipients primed for autoantibody before transplantation.

Conclusions— Passenger CD4 T cells within heart transplants can contribute to allograft vasculopathy by providing help to recipient B cells for autoantibody generation.

Key Words: antibodies • rejection • transplantation • allograft vasculopathy • autoantibody • graft-versus-host-disease • allorecognition


 

CLINICAL PERSPECTIVE